• $700K in new sales orders, 65% increase in annual sales
• 30% reduction in R&D spend, $700K R&D rebate expected
• AI initiatives delivering productivity gains, reducing expenses

Global Health Ltd (ASX: GLH) has released its Appendix 4C Cash Flow Report and Quarterly Business Activity Report for the quarter ended 30 June 2025. The company reported over $700K in new sales orders, with new sales for the financial year up 65% to over $2.4M. Most of the June quarter sales orders will be delivered in subsequent quarters of FY2026. Research and Development expenditure in the June quarter was 20% less than the previous quarter, with the full year investment in R&D reduced by $600K, a 30% reduction year-on-year. A federal government R&D rebate of approximately $700K is expected to be received in the next few months. The company's AI initiatives, established in 2024, are delivering measurable gains in productivity across all departments, expected to deliver further expense reductions. The closing cash of $1,383K at the end of the June quarter was a 66% increase on the previous quarter. With the continued control of costs and adoption of AI, the company is targeting a return to profitable and cashflow positive operations over the 12 months to June 2026.

The company is targeting a return to profitable and cashflow positive operations over the 12 months to June 2026.

The Australian healthcare sector remains challenged, with public healthcare services experiencing increased demand and funding constraints, and private hospitals facing funding pressures. Global Health is well positioned to support healthcare providers through data digitisation and AI adoption to 'do-more-with-less'. The company is also well placed to develop new revenues from both the domestic and international markets as remote services become the norm.